Evolution of biomarker research in autoimmunity conditions for health professionals and clinical practice
Copyright © 2022 Elsevier Inc. All rights reserved..
Medical abzymology has made a great contribution to the development of general autoimmunity theory: it has put the autoantibodies (Ab) as the key brick of the theory to the level of physiological functionality by providing such Ab with the ability to catalyze and mediate direct and independent cytotoxic effect on cellular and molecular targets. Natural catalytic autoantibodies (abzymes) while being a pool of canonical Abs and possessing catalytic activity belong to the new group of physiologically active substances whose features and properties are evolutionary consolidated in one functionally active biomolecule. Therefore, further studies on Ab-mediated autoAg degradation and other targeted Ab-mediated proteolysis may provide biomarkers of newer generations and thus a supplementary tool for assessing the disease progression and predicting disability of the patients and persons at risks. This chapter is a summary of current knowledge and prognostic perspectives toward catalytic Abs in autoimmunity and thus some autoimmune clinical cases, their role in pathogenesis, and the exploitation of both whole molecules and their constituent parts in developing highly effective targeted drugs of the future to come, and thus the therapeutic protocols being individualized.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:190 |
|---|---|
| Enthalten in: |
Progress in molecular biology and translational science - 190(2022), 1 vom: 30., Seite 219-276 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Silverstein, Arthur [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.08.2022 Date Revised 21.09.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/bs.pmbts.2022.02.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM345264053 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM345264053 | ||
| 003 | DE-627 | ||
| 005 | 20231226024652.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/bs.pmbts.2022.02.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1150.xml |
| 035 | |a (DE-627)NLM345264053 | ||
| 035 | |a (NLM)36008000 | ||
| 035 | |a (PII)S1877-1173(22)00041-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Silverstein, Arthur |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evolution of biomarker research in autoimmunity conditions for health professionals and clinical practice |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.08.2022 | ||
| 500 | |a Date Revised 21.09.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Inc. All rights reserved. | ||
| 520 | |a Medical abzymology has made a great contribution to the development of general autoimmunity theory: it has put the autoantibodies (Ab) as the key brick of the theory to the level of physiological functionality by providing such Ab with the ability to catalyze and mediate direct and independent cytotoxic effect on cellular and molecular targets. Natural catalytic autoantibodies (abzymes) while being a pool of canonical Abs and possessing catalytic activity belong to the new group of physiologically active substances whose features and properties are evolutionary consolidated in one functionally active biomolecule. Therefore, further studies on Ab-mediated autoAg degradation and other targeted Ab-mediated proteolysis may provide biomarkers of newer generations and thus a supplementary tool for assessing the disease progression and predicting disability of the patients and persons at risks. This chapter is a summary of current knowledge and prognostic perspectives toward catalytic Abs in autoimmunity and thus some autoimmune clinical cases, their role in pathogenesis, and the exploitation of both whole molecules and their constituent parts in developing highly effective targeted drugs of the future to come, and thus the therapeutic protocols being individualized | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Biomarker | |
| 650 | 4 | |a Multimarker-based companion diagnostics | |
| 650 | 4 | |a Multiple sclerosis | |
| 650 | 4 | |a Next-generation biomarker | |
| 650 | 4 | |a Personalized and precision medicine | |
| 650 | 4 | |a Protein microarrays | |
| 650 | 4 | |a Rheumatoid arthritis | |
| 650 | 4 | |a Targeted therapy | |
| 650 | 4 | |a Western blotting | |
| 650 | 7 | |a Antibodies, Catalytic |2 NLM | |
| 650 | 7 | |a Autoantibodies |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Dudaev, Anton |e verfasserin |4 aut | |
| 700 | 1 | |a Studneva, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Aitken, John |e verfasserin |4 aut | |
| 700 | 1 | |a Blokh, Sofya |e verfasserin |4 aut | |
| 700 | 1 | |a Miller, Andrew David |e verfasserin |4 aut | |
| 700 | 1 | |a Tanasova, Sofia |e verfasserin |4 aut | |
| 700 | 1 | |a Rose, Noel |e verfasserin |4 aut | |
| 700 | 1 | |a Ryals, John |e verfasserin |4 aut | |
| 700 | 1 | |a Borchers, Christoph |e verfasserin |4 aut | |
| 700 | 1 | |a Nordstrom, Anders |e verfasserin |4 aut | |
| 700 | 1 | |a Moiseyakh, Marina |e verfasserin |4 aut | |
| 700 | 1 | |a Herrera, Arturo Solís |e verfasserin |4 aut | |
| 700 | 1 | |a Skomorohov, Nikita |e verfasserin |4 aut | |
| 700 | 1 | |a Marshall, Trevor |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Alan |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, R Holland |e verfasserin |4 aut | |
| 700 | 1 | |a Syzko, Ksenia |e verfasserin |4 aut | |
| 700 | 1 | |a Cotter, Philip D |e verfasserin |4 aut | |
| 700 | 1 | |a Podzyuban, Marianna |e verfasserin |4 aut | |
| 700 | 1 | |a Thilly, William |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Paul David |e verfasserin |4 aut | |
| 700 | 1 | |a Barach, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Bouri, Khaled |e verfasserin |4 aut | |
| 700 | 1 | |a Schoenfeld, Yehuda |e verfasserin |4 aut | |
| 700 | 1 | |a Matsuura, Eiji |e verfasserin |4 aut | |
| 700 | 1 | |a Medvedeva, Veronika |e verfasserin |4 aut | |
| 700 | 1 | |a Shmulevich, Ilya |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Liang |e verfasserin |4 aut | |
| 700 | 1 | |a Seegers, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Khotskaya, Yekaterina |e verfasserin |4 aut | |
| 700 | 1 | |a Flaherty, Keith |e verfasserin |4 aut | |
| 700 | 1 | |a Dooley, Steven |e verfasserin |4 aut | |
| 700 | 1 | |a Sorenson, Eric J |e verfasserin |4 aut | |
| 700 | 1 | |a Ross, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Suchkov, Sergey |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Progress in molecular biology and translational science |d 2008 |g 190(2022), 1 vom: 30., Seite 219-276 |w (DE-627)NLM18554178X |x 1878-0814 |7 nnns |
| 773 | 1 | 8 | |g volume:190 |g year:2022 |g number:1 |g day:30 |g pages:219-276 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/bs.pmbts.2022.02.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 190 |j 2022 |e 1 |b 30 |h 219-276 | ||